Insulet Co. (NASDAQ:PODD) Receives $239.18 Consensus Price Target from Analysts

Insulet Co. (NASDAQ:PODD) has been given an average recommendation of “Moderate Buy” by the eighteen ratings firms that are presently covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $239.18.

A number of research analysts recently commented on PODD shares. Barclays cut their target price on Insulet from $213.00 to $200.00 and set an “equal weight” rating for the company in a research note on Monday, May 13th. OTR Global reiterated a “mixed” rating on shares of Insulet in a research report on Monday, June 10th. Redburn Atlantic assumed coverage on Insulet in a research report on Thursday, May 30th. They issued a “buy” rating and a $235.00 price target on the stock. Raymond James lowered their price target on Insulet from $218.00 to $213.00 and set an “outperform” rating on the stock in a research report on Friday, May 10th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $234.00 price target on shares of Insulet in a research report on Tuesday, July 23rd.

Insulet Stock Performance

Shares of NASDAQ PODD opened at $193.30 on Monday. The business has a fifty day simple moving average of $193.24 and a 200 day simple moving average of $184.45. The company has a current ratio of 3.74, a quick ratio of 2.75 and a debt-to-equity ratio of 1.72. The firm has a market capitalization of $13.54 billion, a price-to-earnings ratio of 58.58, a PEG ratio of 3.47 and a beta of 1.16. Insulet has a one year low of $125.82 and a one year high of $283.00.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, May 9th. The medical instruments supplier reported $0.73 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.34. The business had revenue of $441.70 million during the quarter, compared to analyst estimates of $424.05 million. Insulet had a return on equity of 34.06% and a net margin of 13.14%. Insulet’s revenue was up 23.3% on a year-over-year basis. During the same period in the prior year, the company posted $0.23 earnings per share. Sell-side analysts expect that Insulet will post 3.11 EPS for the current year.

Insider Activity

In other news, Director Timothy J. Scannell sold 3,300 shares of the company’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $180.90, for a total transaction of $596,970.00. Following the transaction, the director now owns 42,586 shares of the company’s stock, valued at $7,703,807.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Insulet news, SVP Mark N. Field sold 2,131 shares of the stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $190.43, for a total value of $405,806.33. Following the transaction, the senior vice president now owns 14,375 shares of the company’s stock, valued at $2,737,431.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Timothy J. Scannell sold 3,300 shares of the stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $180.90, for a total value of $596,970.00. Following the completion of the transaction, the director now directly owns 42,586 shares in the company, valued at approximately $7,703,807.40. The disclosure for this sale can be found here. Insiders have sold 13,931 shares of company stock valued at $2,636,286 over the last 90 days. 0.47% of the stock is owned by company insiders.

Hedge Funds Weigh In On Insulet

Several hedge funds have recently added to or reduced their stakes in PODD. Cooper Financial Group acquired a new position in Insulet in the fourth quarter valued at about $246,000. Wolff Wiese Magana LLC raised its position in shares of Insulet by 2,680.0% during the fourth quarter. Wolff Wiese Magana LLC now owns 139 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 134 shares during the period. CHICAGO TRUST Co NA acquired a new stake in shares of Insulet during the fourth quarter worth about $219,000. Raymond James Financial Services Advisors Inc. raised its position in shares of Insulet by 26.0% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 4,284 shares of the medical instruments supplier’s stock worth $930,000 after purchasing an additional 884 shares during the period. Finally, Assenagon Asset Management S.A. raised its position in shares of Insulet by 119.1% during the fourth quarter. Assenagon Asset Management S.A. now owns 79,375 shares of the medical instruments supplier’s stock worth $17,223,000 after purchasing an additional 43,147 shares during the period.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.